Preliminary results from the INSIGHT 2 clinical trial indicate that combining tepotinib with osimertinib yields a 55% ORR in patients with EGFR-mutated and MET-amplified NSCLC, suggesting that the tepotinib may have potential efficacy in overcoming EGFR-TKI resistance [8]. Here, EGFR is linked to non-small cell lung carcinoma.